BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 4107957)

  • 1. Positive correlation of the long-acting thyroid stimulator (LATS) with the percentage of endogenously labelled 131 I triiodothyronine in the plasma of hyperthyroid patients.
    Emrich D; Albani M; zur Mühlen A von
    Acta Endocrinol (Copenh); 1971 Nov; 68(3):445-50. PubMed ID: 4107957
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical studies of long-acting thyroid stimulator].
    Eguchi Y
    Nihon Naibunpi Gakkai Zasshi; 1970 Nov; 46(8):939-52. PubMed ID: 4099204
    [No Abstract]   [Full Text] [Related]  

  • 3. L.A.T.S. and Graves' disease.
    Hedley AJ; Ross IP; Crooks J
    Lancet; 1970 Aug; 2(7670):468-9. PubMed ID: 4195146
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-acting thyroid stimulator (LATS) in hyperthyroidism and exophthalmos.
    Friis T
    Dan Med Bull; 1969 Nov; 16(10):294-304. PubMed ID: 5392781
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical significance of LATS and TSH in the blood.
    Lemarchand-Béraud T; Griessen M; Scazziga BR
    Ann Clin Res; 1972 Jun; 4(3):121-37. PubMed ID: 4625026
    [No Abstract]   [Full Text] [Related]  

  • 6. The long-acting thyroid stimulator and the result of I 131 treatment for thyrotoxicosis.
    Martin FI; Larkins RG; Alford FP; Andrews JT; Greenberg PB; Melick RA; Penington JS
    Aust N Z J Med; 1972 May; 2(2):168-72. PubMed ID: 4116447
    [No Abstract]   [Full Text] [Related]  

  • 7. Observations against a causal relationship between the long-acting thyroid stimulator and ophthalmopathy in Graves' disease.
    McKenzie JM; McCullagh EP
    J Clin Endocrinol Metab; 1968 Aug; 28(8):1177-82. PubMed ID: 4175472
    [No Abstract]   [Full Text] [Related]  

  • 8. [TSH and the "long-acting thyroid stimulator" (LATS) in patients with compensated hyperthyroidism].
    zur Mühlen A von ; Hesch RD; von Lilienfeld H; Emrich D
    Acta Endocrinol Suppl (Copenh); 1971; 152():86. PubMed ID: 5313711
    [No Abstract]   [Full Text] [Related]  

  • 9. Thyroid suppression and the long-acting thyroid stimulator following radioactive iodine therapy for thyrotoxicosis.
    Alford FP; Larkins RG; Martin FI
    Aust N Z J Med; 1971 Nov; 1(4):339-45. PubMed ID: 5292990
    [No Abstract]   [Full Text] [Related]  

  • 10. Dissociation of serum LATS content and thyroid suppressibility during treatment of hyperthyroidism.
    Chopra IJ; Solomon DH; Johnson DE; Chopra U; Fischer DA
    J Clin Endocrinol Metab; 1970 Apr; 30(4):524-8. PubMed ID: 5435290
    [No Abstract]   [Full Text] [Related]  

  • 11. [Determination of thyrotropic hormone and long acting thyroid stimulator by the McKenzie technique. Critical study of the method].
    Bonnyns M
    Rev Fr Etud Clin Biol; 1968 Nov; 13(9):845-52. PubMed ID: 5709509
    [No Abstract]   [Full Text] [Related]  

  • 12. Occurrence in thyrotoxicosis of a gamma globulin which protects LATS from neutralization by an extract of thyroid gland.
    Adams DD; Kennedy TH
    J Clin Endocrinol Metab; 1967 Feb; 27(2):173-7. PubMed ID: 4163610
    [No Abstract]   [Full Text] [Related]  

  • 13. [The long-acting thyroid stimulator (LATS) in untreated and I-131 treated hyperthyreoses, following total thyroidectomy, as well as its relation to thyroid antibodies].
    Ziemke A; Weisbecker L; Uthgenannt H; Schemmel K; Müller W; Heesen H; Eickenbusch W
    Klin Wochenschr; 1968 Oct; 46(19):1025-7. PubMed ID: 5727481
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies on the nature of plasma thyroid stimulating activity in hyperthyroidism.
    Hoffman MJ; Mason EK; Good BF; Hetzel BS; Ferguson K
    Australas Ann Med; 1967 May; 16(2):98-106. PubMed ID: 4167406
    [No Abstract]   [Full Text] [Related]  

  • 15. The value of IgG separation for the detection of LATS in human serum.
    Bonnyns M; Vanhaelst L
    Clin Exp Immunol; 1969 May; 4(5):597-601. PubMed ID: 5815122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The long acting thyroid stimulator (LATS) in some thyroid diseases. Preliminary results].
    Busnardo B; Accordi F; Debiasi S
    Acta Isot (Padova); 1968 Oct; 8(2):165-79. PubMed ID: 5761578
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence of the long-acting thyroid stimulator (LATS) on radioiodine-labelled thyroxine and triiodothyronine in the thyroid of mice.
    Emrich D; von Toll-Jürgens KH; zur Mühlen A Von
    Endocrinology; 1970 Sep; 87(3):632-6. PubMed ID: 5424582
    [No Abstract]   [Full Text] [Related]  

  • 18. [The determination of long-acting thyroid stimulator (LATS) in thyroid diseases].
    Depisch D; Höfer R; Schatz H
    Wien Z Inn Med; 1968; 49(4):121-30. PubMed ID: 5757238
    [No Abstract]   [Full Text] [Related]  

  • 19. Relation between thyroid function and serum levels of long-acting thyroid stimulator.
    Davis JC; Hipkin LJ; Summers VK; Gimlette TM
    Acta Endocrinol (Copenh); 1975 Jul; 79(3):451-8. PubMed ID: 1173501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypothyroidism after treatment with sodium iodide I-131. Incidence and relationship to antithyroid antibodies, long-acting thyroid stimulator (LATS), and infiltrative ophthalmopathy.
    Burke G; Silverstein GE
    JAMA; 1969 Nov; 210(6):1051-8. PubMed ID: 4900342
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.